Morgan Stanley analyst Patrick Wood maintained a Buy rating on Insulet today and set a price target of $370.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Wood has given his Buy rating due to a combination of factors that highlight Insulet’s strong market position and growth potential. The company has successfully captured a significant share of the market for multiple daily injections (MDI) conversions and is also seeing an increase in competitive conversions. This growth is particularly evident in the contrast with its competitors, as Insulet’s Omnipod is becoming a preferred choice among prescribers and patients, especially for Type 2 diabetes. The favorable reimbursement trends that support pay-as-you-go models further strengthen Insulet’s position.
Additionally, Insulet’s impressive growth in the U.S. market, with a consistent 25-35% increase in Omnipod sales since 2019, is complemented by remarkable international sales growth. The international market for Type 1 diabetes, which is twice the size of the U.S. market but with only half the penetration, presents a significant opportunity for Insulet. This underappreciated aspect of their business, along with the company’s ability to scale unit economics and expand margins, supports the upward revision of sales estimates and the increase in the price target to $370. These factors collectively justify the Buy rating.
In another report released today, Jefferies also maintained a Buy rating on the stock with a $375.00 price target.